ArticleJournal of multidisciplinary healthcare2025
Insights into Omicron: Genomic Characterization and Inpatient Risk Assessment at Single Tertiary Hospital in Indonesia.
Article in Journal of multidisciplinary healthcare, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Omicron is a variant with the highest number of mutations among all Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) viruses, making whole genome sequencing (WGS) an essential tool for public health surveillance and molecular epidemiology. It is important to note that surveillance data can provide insights into the virus evolution and disease control. This study aims to provide an overview of WGS results for the SARS-CoV-2 Omicron Variant at Hasan Sadikin General Hospital Bandung. Patients and Methods: This study was conducted using an analytical observational method. Data was collected retrospectively from medical records, SARS-CoV-2 reverse transcriptase polymerase chain reaction (RT-PCR) results, and WGS results of patients at Hasan Sadikin General Hospital Bandung from July to December 2022, who met the inclusion criteria. The lineage trends, mutation profiles, characteristics differences, and factors influencing hospitalization were also described. Results: Among 239 subjects, 50 Omicron lineages were identified, with BA.5.2 (28%) and XBB.1 (19.2%) dominating since July and October 2022, respectively. The spike gene had the highest frequency, accounting for 28.8% out of the 532 types of mutations identified. In BA.5.2 lineage, 97.01, 92.53, and 100% had L452R mutation, F486V mutation, and H69/V70 deletion, respectively. In the XBB.1 lineage, 100% had R346T and N460K mutations, with no H69/V70 deletion observed. XBB.1 lineage was associated with a 5.49 times greater risk of inpatient treatment (95% CI: 1.73-17.38) compared to BA.5.2, while the adjusted odds ratio (aOR) for the number of vaccinations was 0.45 (95% CI: 0.29-0.7). Conclusion: BA.5.2 and XBB.1 lineage dominated Omicron variant infections from July to December 2022, with the most mutations occurring in the spike gene. Inpatient risk was influenced by the type of lineage, with XBB.1 showing a higher risk. A greater number of vaccinations significantly reduced this risk, emphasizing the protective role of vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.